RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
- 7 June 2019
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 60 (13), 3181-3187
- https://doi.org/10.1080/10428194.2019.1622700
Abstract
Most patients with lower risk myelodysplastic syndromes (LR-MDS) become red blood cell (RBC) transfusion dependent at some time during their disease course. Hypomethylating agents (HMAs) are frequently used in this setting; however, reported rates of in RBC transfusion independence (TI) achieved with HMA therapy vary significantly between studies. Here we study the real-life clinical effectiveness of HMA in inducing RBC TI in anemic LR-MDS patients using the Surveillance, Epidemiology and End Results (SEER)-Medicare database. We find that approximately 40% of LR-MDS patients who were receiving RBC transfusions and 33% who were dependent on RBC transfusions at HMA initiation ultimately achieved TI. The receipt of ≥3 transfusions in the 8-week period before HMA initiation was significantly associated with lower odds of achieving TI. Our study provides important population level estimates of clinical effectiveness of HMAs in LR-MDS.Keywords
This publication has 23 references indexed in Scilit:
- Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromesAnnals of Hematology, 2018
- Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsJournal of Clinical Oncology, 2017
- Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsExpert Review of Hematology, 2017
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsJournal of Clinical Oncology, 2016
- Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-AnalysisActa Haematologica, 2016
- How we treat lower-risk myelodysplastic syndromesBlood, 2013
- Azacitidine in lower-risk myelodysplastic syndromesLeukemia Research, 2009
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood, 2008
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002